Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising. METHODS: We co...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Dermatol Ther (Heidelb)
Auteurs principaux: Farahnik, Benjamin, Beroukhim, Kourosh, Zhu, Tian Hao, Abrouk, Michael, Nakamura, Mio, Singh, Rasnik, Lee, Kristina, Bhutani, Tina, Koo, John
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2016
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4799032/
https://ncbi.nlm.nih.gov/pubmed/26910853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-016-0102-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires